Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01948414
Other study ID # 2012.784
Secondary ID
Status Completed
Phase N/A
First received September 2, 2013
Last updated August 26, 2016
Start date July 2013
Est. completion date June 2015

Study information

Verified date August 2016
Source Hospices Civils de Lyon
Contact n/a
Is FDA regulated No
Health authority France: Agence Nationale de Sécurité du Médicament et des produits de santé
Study type Interventional

Clinical Trial Summary

The P300 is one of the cognitive wave of the Event-Related Potential (ERP) that is used to investigate the cognitive process. The P300 component are accepted as electro-physiological markers of neuropsychiatric disorders like alcoholism or drug addiction.

Recent scientific data suggest that eating disorders, leading to weight gain and obesity, will be similar of those of drug addiction: it is the incentive sensitization theory that implicates the dopaminergic reward system.

The aim of this cross-sectional study is to investigate the alteration of P300 auditory ERP in obese women with eating disorders in comparison with obese and lean women without eating disorders.


Recruitment information / eligibility

Status Completed
Enrollment 108
Est. completion date June 2015
Est. primary completion date June 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 20 Years to 55 Years
Eligibility Inclusion Criteria:

- women

- Aged from 20 to 55 years

- Fasting glycemia under 7mmol/L

- Lean women : women with BMI from 18.5 to 24.5 and disinhibition score to Three-Factor Eating Questionnaire (TFEQ)lower or equal to 8

- Obese women without eating disorders : women with BMI higher or equal to 35 and disinhibition score to TFEQ lower or equal to 8

- Obese women with eating disorders : women with BMI higher or equal 35 and disinhibition score to TFEQ strictly higher to 8

Exclusion Criteria:

- Subject not in compliance with the recommendations of French National Law in force

- Medical history of diabetes and surgery history of obesity

- Drug use that could affect the ERP recording

- Hospital Anxiety and Depression scale : evaluation subscale (anxiety and/or depression) strictly higher to 11

Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science


Intervention

Procedure:
electroencephalography

Biological:
Blood sampling

Behavioral:
Questionnaires regarding eating habits (TFEQ, EDI) and anxiety/depression (HAD)


Locations

Country Name City State
France CRNH Rhône-Alpes /CENS Centre Européen pour la Nutrition et la Santé Centre Hospitalier Lyon Sud - Pavillon médical 165, chemin du Grand Revoyet Pierre Bénite

Sponsors (1)

Lead Sponsor Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary P300 amplitude The auditory event-related potentials measure will be elicited with an auditory oddball paradigm. The activity will be recorded thanks to electroencephalography from frontal, central and parietal electrodes, using an electrode cap. At the beginning of the exploration visit (when patient is fasting) that will take place between 1 and 15 days after inclusion No
Secondary Auditory ERP ( latency P300, amplitude and latency of N2 wave recorded from frontal, central and parietal electrode) The technique of auditory ERP will be an auditory discriminated task paradigm fasting (up to 15 days) No
Secondary assessment of dietary restraints and disinhibition Participants will complete self-report questionnaires including Three-Factor Eating Questionnaire and Eating Disorders Inventory. The lean subjects should not have TFEQ disinhibition score more than 8. The obese subjects will be separated on two groups depending on TFEQ dishinibition score (strictly greater than 8, the obese with eating disorder, less than or equal 8, obese without eating disorder). fasting (up to 15 days) No
Secondary glucose, insulin, leptin and ghrelin plasmatic rate respectively reverse-phase high-performance liquid chromatography (RP-HPLC), ImmunoRadio Metric (IRMA) and ELISA assay fasting (up to 15 days) No
Secondary dopamine D2 receptor Taq 1 polymorphism Real time PCR fasting (up to 15 days) No
Secondary Dietary intake and eating patterns Women will be interviewed by dietician, using a 24 h food questionnaire with additional questions regarding health and eating habits At day 1 and at day 15 No

External Links